摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(5,6,7,8-四氢-8-喹啉基)-乙酰胺 | 477531-98-9

中文名称
N-(5,6,7,8-四氢-8-喹啉基)-乙酰胺
中文别名
——
英文名称
N-(5,6,7,8-tetrahydroquinolin-8-yl)acetamide
英文别名
8-acetamido-5,6,7,8-tetrahydroquinoline;(R,S)-N-(5,6,7,8-tetrahydroquinolin-8-yl)-acetamide;N-(5,6,7,8-tetrahydroquinolin-8-yl)-acetamide
N-(5,6,7,8-四氢-8-喹啉基)-乙酰胺化学式
CAS
477531-98-9
化学式
C11H14N2O
mdl
——
分子量
190.245
InChiKey
UQIDJMAPFDKIBY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    420.5±24.0 °C(Predicted)
  • 密度:
    1.13±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of Novel Small Molecule Orally Bioavailable C−X−C Chemokine Receptor 4 Antagonists That Are Potent Inhibitors of T-Tropic (X4) HIV-1 Replication
    摘要:
    The redesign of azamacrocyclic CXCR4 chemokine receptor antagonists resulted in the discovery of novel, small molecule, orally bioavailable compounds that retained T-tropic (CXCR4 using, X4) anti-HIV-1 activity. A structure activity relationship (SA R) was determined on the basis of the inhibition of replication of X4 HIV-1 NL4.3 in MT-4 cells. As a result of lead optimization, we identified (S)-N'-((1H-benzo[d]imidazol-2-Amethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine (AMD070) 2 as a potent and selective antagonist of CXCR4 with an IC(50) value of 13 nM in a CXCR4 (125)I-SDF inhibition binding assay. Compound 2 inhibited the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC(50) of 2 and 26 nM, respectively, while remaining noncytotoxic to cells at concentrations exceeding 23 mu M. The pharmacokinetics of 2 was evaluated in rat and dog, and good oral bioavailability was observed in both species. This compound represents the first small molecule orally bioavailable CXCR4 antagonist that was developed for the treatment of HIV-1 infection.
    DOI:
    10.1021/jm100073m
  • 作为产物:
    描述:
    N-[(8R)-5,6,7,8-四氢-8-喹啉基]-乙酰胺 反应 0.5h, 以100%的产率得到N-(5,6,7,8-四氢-8-喹啉基)-乙酰胺
    参考文献:
    名称:
    Enzymatic Resolution of Bicyclic 1-Heteroarylamines Using Candida antarctica Lipase B
    摘要:
    Candida antarctica lipase B has been used to kinetically resolve a structurally diverse series of bicyclic 1-heteroaryl primary amines by enantioselective acetylation. High yields of either enantiomer could be obtained with excellent enantioselectivity (90-99% ee), while the undesired enantiomer could, in some cases be recycled by thermal racemization. The absolute stereochemistry of the products was confirmed by an X-ray crystal structure.
    DOI:
    10.1021/jo026701r
点击查看最新优质反应信息

文献信息

  • Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
    申请人:——
    公开号:US20030114679A1
    公开(公告)日:2003-06-19
    This invention describes various processes for synthesis and resolution of racemic amino-substituted fused bicyclic ring systems. One process utilizes selective hydrogenation of an amino-substituted fused bicyclic aromatic ring system. An alternative process prepares the racemic amino-substituted fused bicyclic ring system via nitrosation. In addition, the present invention describes the enzymatic resolution of a racemic mixture to produce the (R)- and (S)-forms of amino-substituted fused bicyclic rings as well as a racemization process to recycle the unpreferred enantioner. Further provided by this invention is an asymmetric synthesis of the (R)- or (S)-enantiomer of primary amino-substituted fused bicyclic ring systems.
    该发明描述了合成和分离外消旋基取代的融合双环环系统的各种过程。其中一种过程利用选择性氢化基取代的融合双环芳香环系统。另一种替代过程通过亚硝化制备外消旋基取代的融合双环环系统。此外,该发明描述了酶催化拆分外消旋混合物,以生产基取代的融合双环环的(R)-和(S)-形式,以及一个消旋过程来回收未优选的对映体。该发明还提供了外消旋基取代的融合双环环系统的(R)-或(S)-对映体的不对称合成。
  • Concise Preparation of Amino-5,6,7,8-tetrahydroquinolines and Amino-5,6,7,8-tetrahydroisoquinolines via Catalytic Hydrogenation of Acetamidoquinolines and Acetamidoisoquinolines
    作者:Krystyna A. Skupinska、Ernest J. McEachern、Renato T. Skerlj、Gary J. Bridger
    DOI:10.1021/jo026258k
    日期:2002.11.1
    via catalytic hydrogenation of the corresponding acetamido-substituted quinolines and isoquinolines followed by acetamide hydrolysis is described. The yields of the products are good when the acetamido substituent is present on the pyridine ring and moderate with the acetamido substituent on the benzene ring. This method has also been applied to the regioselective reduction of quinoline substrates bearing
    描述了一种通过相应的乙酰胺基取代的喹啉异喹啉的催化氢化,然后乙酰胺解制备基取代的5,6,7,8-四氢喹啉和5,6,7,8-四氢异喹啉的方法。当乙酰基取代基存在于吡啶环上且与乙酰基取代基在苯环上适度结合时,产物的收率良好。此方法也已应用于带有其他取代基(R = OMe,CO(2)Me,Ph)的喹啉底物的区域选择性还原。
  • EP1487795A4
    申请人:——
    公开号:EP1487795A4
    公开(公告)日:2005-02-09
  • SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS
    申请人:ANORMED INC.
    公开号:EP1487795A2
    公开(公告)日:2004-12-22
  • US6825351B2
    申请人:——
    公开号:US6825351B2
    公开(公告)日:2004-11-30
查看更多